Davis Krista 4

What Happened
Krista Davis, Senior Vice President and Chief HR Officer of ANI Pharmaceuticals, sold a total of 3,814 shares in two open‑market transactions. On 2026-02-19 she sold 2,084 shares at $77.53 each for $161,573, and on 2026-02-20 she sold 1,730 shares at $77.99 each for $134,923 — total proceeds about $296,496. These were sales (not purchases), which are often routine disposition of holdings.

Key Details

• Transaction dates and prices: 2026-02-19 (2,084 shares @ $77.53); 2026-02-20 (1,730 shares @ $77.99). Footnote indicates trades occurred at prices from $77.45 to $78.58 and the reported prices are weighted averages.
• Total shares sold: 3,814; total proceeds: ~$296,496.
• Plan/footnote: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by Davis on September 18, 2025 (pre‑arranged plan).
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing — see the full Form 4 for post‑transaction holdings.
• Filing timeliness: Form 4 was filed 2026-02-23; the filing appears to be within the SEC’s 2‑business‑day reporting window for these trades.

Context
Because the sales were executed under a pre‑arranged 10b5‑1 plan, they are generally viewed as routine and not a real‑time signal of the insider’s view on the stock. For retail investors, purchases tend to carry more informational weight than scheduled sales; consult the full Form 4 for holdings and other company insider activity.